2022 Packaging Printing Market International Trends and Analysis

ReportsWeb.com added “Global Packaging Printing Detailed Analysis Report 2017-2022” to its vast collection of research Database. The report is spread across 119 pages and supported by 19 company leaders.

The Global Packaging Printing Detailed Analysis Report 2017-2022 is a professional and in-depth study on the current state of the Packaging Printing industry. In a word, This report studies Packaging Printing in Global market, especially in North America, Latin America, Europe, Asia & Pacific and Africa & Middle East, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer. Key companies included in this research are Major Companies, Eastman Kodak Co. (U.S.), Quantum Print and Packaging Ltd. (U.K.), Toppan Printing co, ltd. (Japan), Quad/Graphics Inc. (U.S.),  Traco Manufacturing, Inc. (U.S.), HP Inc. (U.S.), E.I. du Pont de Nemours and Company (U.S.), Xerox Corporation (U.S.), WS Packaging Group, Inc. (U.S.), Mondi plc (South Africa).

This report mainly introduces volume and value market share by players, by regions, by product type, by consumers and also their price change details. As a Detailed Analysis report, it covers all details inside analysis and opinion in Packaging Printing industry. This report splits Packaging Printing market By Forging Mode, By Pressure, By Control Type, which covers the history data information from 2012 to 2016 and forecast from 2017 to 2022.

Browse complete report @ http://www.reportsweb.com/global-packaging-printing-detailed-analysis-report-2017-2022

Market Segment by Region, this report splits Global into several key Region, with sales, revenue, market share and growth rate of Packaging Printing in these regions, from 2011 to 2022 (forecast), like North America, Latin America, Europe, Asia & Pacific and Africa & Middle East. Firstly, Packaging Printing Market Main Product Type
Packaging Printing Market, by Printing Ink
Packaging Printing Market, by Printing Technology
Flexography printing
Rotogravure printing
Offset printing
Digital printing
Screen Printing
Packaging Printing Market, by Materials
Paper & paperboard

Main Applications
Food & beverage
Household & cosmetic products

Request for Sample @ http://www.reportsweb.com/inquiry&RW0001997419/sample

Major points from Table of Contents:

Chapter One Packaging Printing Market Overview

Chapter Two, Packaging Printing by Regions 2012-2022

Chapter Three, Packaging Printing by Brands 2012-2022

Chapter Four, Packaging Printing by Consumer 2012-2022

Chapter Five Global Top Players Profile
5.1 Eastman Kodak Co. (U.S.)
5.1.1 Eastman Kodak Co. (U.S.) Company Details and Competitors
5.1.2 Eastman Kodak Co. (U.S.) Key Packaging Printing Models and Performance
5.1.3 Eastman Kodak Co. (U.S.) Packaging Printing Business SWOT Analysis and Forecast
5.1.4 Eastman Kodak Co. (U.S.) Packaging Printing Sales Volume Revenue Price Cost and Gross Margin
5.2 Quantum Print and Packaging Ltd. (U.K.)
5.2.1 Quantum Print and Packaging Ltd. (U.K.) Company Details and Competitors
5.2.2 Quantum Print and Packaging Ltd. (U.K.) Key Packaging Printing Models and Performance
5.2.3 Quantum Print and Packaging Ltd. (U.K.) Packaging Printing Business SWOT Analysis and Forecast
5.2.4 Quantum Print and Packaging Ltd. (U.K.) Packaging Printing Sales Volume Revenue Price Cost and Gross Margin
5.3 Toppan Printing co, ltd. (Japan)
5.3.1 Toppan Printing co, ltd. (Japan) Company Details and Competitors
5.3.2 Toppan Printing co, ltd. (Japan) Key Packaging Printing Models and Performance
5.3.3 Toppan Printing co, ltd. (Japan) Packaging Printing Business SWOT Analysis and Forecast
5.3.4 Toppan Printing co, ltd. (Japan) Packaging Printing Sales Volume Revenue Price Cost and Gross Margin
5.4 Quad/Graphics Inc. (U.S.)
5.4.1 Quad/Graphics Inc. (U.S.) Company Details and Competitors
5.4.2 Quad/Graphics Inc. (U.S.) Key Packaging Printing Models and Performance
5.4.3 Quad/Graphics Inc. (U.S.) Packaging Printing Business SWOT Analysis and Forecast
5.4.4 Quad/Graphics Inc. (U.S.) Packaging Printing Sales Volume Revenue Price Cost and Gross Margin

Chapter Six, Industry Chain and Supply Chain

Chapter Seven, Development Trend and Research Conclusion

List of Tables and Figures

Table Global Packaging Printing Sales Volume (K USD/Unit), Revenue (Million USD) and Price (Units)(2012-2017)
Figure Global Packaging Printing Revenue (Million USD) and Growth Rate (2012-2017)
Figure Global Packaging Printing Sales Volume (K USD/Unit) and Growth Rate (2012-2017)
Table Global Packaging Printing Sales (K USD/Unit) by Forging Mode (2012-2017)
Table Global Packaging Printing Sales Market Share by Forging Mode (2012-2017)
Figure Global Packaging Printing Sales Market Share by Forging Mode in 2016
Table Global Packaging Printing Revenue (Million USD) by Forging Mode (2012-2017)
Table Global Packaging Printing Revenue Market Share by Forging Mode (2012-2017)
Figure Global Packaging Printing Revenue Market Share by Forging Mode in 2016
Table Global Packaging Printing Price (Units) by Forging Mode (2012-2017)
Table Top Players of Closed Die Forging Packaging Printing Products List
Figure Global Closed Die Forging Packaging Printing Sales (K USD/Unit) and Growth Rate (2012-2017)
Table Top Players of Open Die Forging Packaging Printing Products List
Figure Global Open Die Forging Packaging Printing Sales (K USD/Unit) and Growth Rate (2012-2017)
Table Top Players of Extrusion Presses Packaging Printing Products List
Figure Global Extrusion Presses Packaging Printing Sales (K USD/Unit) and Growth Rate (2012-2017)
Table Top Players of Other Packaging Printing Products List
Figure Global Other Packaging Printing Sales (K USD/Unit) and Growth Rate (2012-2017)
Table Global Packaging Printing Sales (K USD/Unit) by Pressure (2012-2017)
Table Global Packaging Printing Sales Market Share by Pressure (2012-2017)
Figure Global Packaging Printing Sales Market Share by Pressure in 2016
Table Global Packaging Printing Revenue (Million USD) by Pressure (2012-2017)
Table Global Packaging Printing Revenue Market Share by Pressure (2012-2017)
Figure Global Packaging Printing Revenue Market Share by Pressure in 2016
Table Global Packaging Printing Price (Units) by Pressure (2012-2017)
Table Top Players of 25MN Packaging Printing Products List
Figure Global 25MN Packaging Printing Sales (K USD/Unit) and Growth Rate (2012-2017)

Place a DIRECT Purchase order of complete report @ http://www.reportsweb.com/buy&RW0001997419/buy/3250 . Else place an Inquire before Purchase “Global Packaging Printing Industry 2017 research study” @ http://www.reportsweb.com/inquiry&RW0001997419/buying .

Contact Info:
Name: Sameer Joshi
Email: sales@reportsweb.com
Organization: ReportsWeb
Phone: +1-646-491-9876

ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Engelstad Family Foundation Pledges $10 million Gift to Advance Roseman University’s College of Medicine

- Donation leads $66 million campaign -

LAS VEGAS, Sept. 7, 2017 /PRNewswire-USNewswire/ -- Roseman University College of Medicine today announced a $10 million pledge gift from the Engelstad Family Foundation to help advance the opening of Nevada's first private, non-profit, MD-granting medical school in Summerlin.

The donation, the largest in Roseman University's history, kicks off "Breakthrough in Medicine!," a $66 million fundraising campaign that will ensure the College of Medicine fulfills its mission to improve the health of the communities in southern Nevada by providing funding to hire the critical faculty and staff needed as it continues through the rigorous accreditation process. The College of Medicine is currently an applicant with the Liaison Committee on Medical Education (LCME) and has a goal to achieve accreditation to enroll its first class of 64 students in the summer of 2019.

"In addition to the institutional resources provided by Roseman University, this pledged gift is a significant step in our effort to raise the $66 million needed to establish a premier private, MD-granting medical school that will help Nevada communities overcome the chronic shortage of physicians and improve healthcare outcomes," said Mark A. Penn, MD, MBA, founding dean of the Roseman University College of Medicine.

"As a non-profit, private medical school, built without the support of state funding, we are extremely grateful for the generosity and support of the Engelstad Family Foundation and the many business and community members who have also embraced our mission and vision, and supported the College with philanthropic gifts. Additional support is needed as we work towards our goal of raising $66 million," added Penn.

In making the donation, the Engelstad Family Foundation stated, "The Engelstad Family Foundation applauds the work of Roseman University College of Medicine and their endeavor to raise $66 million to ultimately improve healthcare in Southern Nevada through their 'Breakthrough in Medicine' campaign for Roseman University's medical school in Summerlin – the first of its kind in Nevada."

According to Roseman University President Renee Coffman, PhD, in making this landmark pledge gift, the Engelstad Family Foundation will help transform the healthcare landscape in Nevada. "Roseman University and the Engelstad Family Foundation have a shared vision for our state's future – a Nevada where every resident has access to high-quality primary care and medical specialties," said Coffman.

About the Roseman University College of Medicine
Roseman University began building the foundation for its MD-granting College of Medicine in 2010 through the establishment of medical research programs. On December 13, 2013, the Board of Trustees of Roseman University unanimously approved the university's plan to develop an allopathic medical school in Southern Nevada. The College of Medicine is housed at Roseman University's Summerlin campus.

About Roseman University of Health Sciences
Founded in Henderson, Nevada in 1999, Roseman University of Health Sciences is a non-profit, private institution of higher learning training the next generation of undergraduate and graduate level health care professionals that serve, collaborate and set new standards in their communities and within their professions. With campuses in Henderson, Summerlin in Nevada and South Jordan, Utah, the University is comprised of the College of Dental Medicine, offering an Advanced Education in Orthodontics and Dentofacial Orthopedics/MBA residency, Advance Education in General Dentistry residency and Doctor of Dental Medicine program; College of Pharmacy, offering a Doctor of Pharmacy and Professional Continuing Education; College of Nursing, offering a Bachelor of Science in Nursing, Accelerated Bachelor of Science in Nursing and RN to BSN; and an healthcare focused MBA program. Roseman University of Health Sciences will also offer a Doctor of Medicine through its College of Medicine once it becomes accredited. More than 4,000 Roseman graduates are caring for patients, conducting research, and engaged in public health and policy in Nevada, Utah and across the country. Roseman University is regionally accredited by the Northwest Commission on Colleges and Universities.


View original content with multimedia:http://www.prnewswire.com/news-releases/engelstad-family-foundation-pledges-10-million-gift-to-advance-roseman-universitys-college-of-medicine-300515862.html

SOURCE Roseman University of Health Sciences

Champions Oncology to Announce First Quarter Financial Results on Thursday, September 14, 2017

HACKENSACK, N.J., Sept. 7, 2017 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the first quarter ended July 31, 2017, on Thursday, September 14, 2017, after market close.

The company will host a conference call to discuss the results that day at 5:00 p.m. EST (2:00 p.m. PST). To participate in the call, please call 866-682-6100 (domestic) or 404-267-0373 (international) ten minutes ahead of the call and give the verbal reference "Champions Oncology."

A replay of the call will be available on the Investor tab of the company's website within 72 hours.

About Champions Oncology, Inc.

Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs.  The Company's TumorGraft technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen.  The Company uses this technology in conjunction with related services to offer solutions for two customer groups:  Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through Champions' Personalized Oncology Solutions business. For more information, please visit www.championsoncology.com.

View original content:http://www.prnewswire.com/news-releases/champions-oncology-to-announce-first-quarter-financial-results-on-thursday-september-14-2017-300515798.html

SOURCE Champions Oncology, Inc.

Alcohol Justice Reports: Alcohol industry misleading the public about alcohol-related cancer risk

Study identifies "denying, distortion and distraction" as main strategies

SAN FRANCISCO, Sept. 7, 2017 /PRNewswire-USNewswire/ -- Alcohol Justice is reporting the release of a new study in the UK showing that the alcohol industry (AI) is misrepresenting evidence about the alcohol-related risk of cancer with activities that have parallels with those of the tobacco industry. The new research is published in the journal Drug and Alcohol Review.

Led by the London School of Hygiene & Tropical Medicine with the Karolinska Institutet, Sweden, the team analysed the information relating to cancer which appears on the websites and documents of nearly 30 alcohol industry organisations around the world between September 2016 and December 2016. Most of the organisational websites (24/26) showed some sort of distortion or misrepresentation of the evidence about alcohol-related cancer risk, with breast and colorectal cancers being the most common focus of misrepresentation

The most common approach involves presenting the relationship between alcohol and cancer as highly complex, with the implication or statement that there is no evidence of a consistent or independent link. Others include denying that any relationship exists or claiming inaccurately that there is no risk for light or 'moderate' drinking, as well discussing a wide range of real and potential risk factors, thus presenting alcohol as just one risk among many.

"This study exposes Big Alcohol's standard operating procedure - deny, distract and distort evidence of alcohol as a dangerous disease-causing agent," stated Bruce Lee Livingston, Executive Director / CEO of U.S-based Alcohol Justice. "It is further evidence that any and all health claims made by the alcohol industry are nothing more than marketing rhetoric making it culpable for fueling over-consumption and massive related harm worldwide."

According to the study, the researchers say policymakers and public health bodies should reconsider their relationships to these alcohol industry bodies, as the industry is involved in developing alcohol policy in many countries, and disseminates health information to the public.

Alcohol consumption is a well-established risk factor for a range of cancers, including oral cavity, liver, breast and colorectal cancers, and accounts for about 4% of new cancer cases annually in the UK1. There is limited evidence that alcohol consumption protects against some cancers, such as renal and ovary cancers, but in 2016 the UK's Committee on Carcinogenicity concluded that the evidence is inconsistent, and the increased risk of other cancers as a result of drinking alcohol far outweighs any possible decreased risk².

This new study analysed the information which is disseminated by 27 AI-funded organisations, most commonly 'social aspects and public relations organisations' (SAPROs), and similar bodies. The researchers aimed to determine the extent to which the alcohol industry fully and accurately communicates the scientific evidence on alcohol and cancer to consumers.

They analysed information on cancer and alcohol consumption disseminated by alcohol industry bodies and related organisations from English speaking countries, or where the information was available in English.

Through qualitative analysis of this information they identified three main industry strategies. Denying, or disputing any link with cancer, or selective omission of the relationship, Distortion: mentioning some risk of cancer, but misrepresenting or obfuscating the nature or size of that risk and Distraction: focussing discussion away from the independent effects of alcohol on common cancers.

Mark Petticrew, Professor of Public Health at the London School of Hygiene & Tropical Medicine and lead author of the study, said: "The weight of scientific evidence is clear - drinking alcohol increases the risk of some of the most common forms of cancer, including several common cancers. Public awareness of this risk is low, and it has been argued that greater public awareness, particularly of the risk of breast cancer, poses a significant threat to the alcohol industry. Our analysis suggests that the major global alcohol producers may attempt to mitigate this by disseminating misleading information about cancer through their 'responsible drinking' bodies."

A common strategy was 'selective omission' - avoiding mention of cancer while discussing other health risks or appearing to selectively omit specific cancers. The researchers say that one of the most important findings is that AI materials appear to specifically omit or misrepresent the evidence on breast and colorectal cancer. One possible reason is that these are among the most common cancers, and therefore may be more well-known than oral and oesophageal cancers.

When breast cancer is mentioned the researchers found that 21 of the organisations present no, or misleading, information on breast cancer, such as presenting many alternative possible risk factors for breast cancer, without acknowledging the independent risk of alcohol consumption.

Professor Petticrew said: "Existing evidence of strategies employed by the alcohol industry suggests that this may not be a matter of simple error. This has obvious parallels with the global tobacco industry's decades-long campaign to mislead the public about the risk of cancer, which also used front organisations and corporate social activities."

The researchers say the results are important because the alcohol industry is involved in conveying health information to people around the world. The findings also suggest that major international alcohol companies may be misleading their shareholders about the risks of their products, potentially leaving the industry open to litigation in some countries.

Professor Petticrew said: "Some public health bodies liaise with the industry organisations that we analysed. Despite their undoubtedly good intentions, it is unethical for them to lend their expertise and legitimacy to industry campaigns which mislead the public about alcohol-related harms. Our findings are also a clear reminder of the risks of giving the AI the responsibility of informing the public about alcohol and health.

"It has often been assumed that, by and large, the AI, unlike the tobacco industry, has tended not to deny the harms of alcohol. However, through its provision of misleading information it can maintain what has been called 'the illusion of righteousness' in the eyes of policymakers, while negating any significant impact on alcohol consumption and profits.

"It's important to highlight that if people drink within the recommended guidelines they shouldn't be too concerned when it comes to cancer. For accurate and accessible information on the risks, the public can visit the NHS website."

The authors acknowledge limitations of their study including that there are many other mechanisms and organisations through which industry disseminates health-related information which they did not examine, although it is unlikely that the messages would be different.

The researchers also say there is an urgent need to examine other industry websites, documents, social media and other materials in order to assess the nature and extent of the distortion of evidence, and whether it extends to other health information, for example, in relation to cardiovascular disease.

For more information or to request interviews please contact the London School of Hygiene & Tropical Medicine press office on +44(0)20 7927 2802 or email press@lshtm.ac.uk.

A copy of the paper is available upon request.

Notes to Editors


Mark Petticrew, Nason Maani Hessari ,Cécile knai and Elisabete Weiderpass. How alcohol industry organisations mislead the public about alcohol and cancer. Drug and Alcohol Review. DOI: 10.1111/dar.12596

1Cancer Research UK: Statistics on preventable cancers.

2Committee on Carcinogenicity of chemicals in food, consumer products and the environment (COC). Statement 2015/S2.

About the London School of Hygiene & Tropical Medicine

The London School of Hygiene & Tropical Medicine is a world-leading centre for research and postgraduate education in public and global health, with more than 4,000 students and 1,000 staff working in over 100 countries. The School is one of the highest-rated research institutions in the UK, is among the world's leading schools in public and global health, and was named University of the Year in the Times Higher Education Awards 2016. Our mission is to improve health and health equity in the UK and worldwide; working in partnership to achieve excellence in public and global health research, education and translation of knowledge into policy and practice. http://www.lshtm.ac.uk

View original content with multimedia:http://www.prnewswire.com/news-releases/alcohol-justice-reports-alcohol-industry-misleading-the-public-about-alcohol-related-cancer-risk-300515978.html

SOURCE Alcohol Justice

Nurses Nationwide Lend a Helping Hand at Bay Area Regional in the Aftermath of Hurricane Harvey

WEBSTER, Texas, Sept. 7, 2017 /PRNewswire/ -- Nurses from New Jersey, New York, California and Massachusetts made their way to Bay Area Regional Medical Center in the days after impact to relieve staff to get much needed rest and to begin the process of cleanup and rebuilding.

Bay Area Regional employees weathered the storm at the hospital for many days. Most slept in the hospital because of massive, widespread flooding. "Some essential staff was rescued by boat and by large vehicles when the flooding first began," said Stephen K. Jones, Jr., CEO of Bay Area Regional Medical Center. "Thanks to many folks, we were able to rescue and transport many staff to the hospital. Many of whom had significant water damage to their homes and vehicles."

Nurses from New Jersey landed at Ellington Field August 31 and have spent time helping at the hospital and volunteering to demo nurses flooded homes along with volunteering at shelters.

"I am humbled and in awe at the generosity and positive attitudes the wonderful community and staff of Bay Area Regional Medical Center have expressed toward us in light of the hardship they have endured," said Brenda Lima-Mattessich, RN from AtlantiCare in New Jersey. "I worked 18-20 hours a day during Hurricane Sandy, so I know what the nurses here are going through. Everyone has embraced us with humbleness and grace."

Vanessa Jones, RN from Capital Health in New Jersey commented, "We came here to help and we are leaving with a sense of family and relationships that we will have for years to come."

Bay Area Regional was "designed to withstand a category five hurricane with 225 mph winds and designed with the future mind in strength, quality and state-of-the-art equipment," said Monzer Hourani, CEO of Medistar Corp. "While other hospitals had to evacuate or stop accepting patients, Bay Area Regional remained open and was unaffected structurally by the storm. In fact, the National Guard delivered patients to our hospital." 

Relief efforts are still underway as the hospital welcomed nurses from Massachusetts on September 6 in the afternoon. "I am honored to have so many nurses from across the country ready to assist our staff in the recovery efforts after Hurricane Harvey," said Jones, Jr. "We are truly blessed by each person who got on an airplane to come to the Houston Bay Area and lend a helping hand to our wonderful community."

About Bay Area Regional Medical Center
Bay Area Regional Medical Center is committed to providing the highest quality medical care while making a difference in people's lives. Designed with a beautiful, soothing environment, Bay Area Regional offers some of the latest technology for physicians to provide advanced diagnostic and treatment techniques. Since opening in July 2014, Bay Area Regional has achieved the highest level Chest Pain Center Accreditation, is in pursuit of Level III Trauma Designation, and has achieved a Center of Excellence for Bariatric Surgery and Hidden Scar Breast Surgery. The hospital offers services such as heart and vascular services, general surgery, orthopedics, emergency services, surgical weight-loss, outpatient imaging, including 3D Mammography with a new Women's OB unit opening in September 2017. For more information, visit www.BARMC.us.

Contact: Abbey Lee
832-585-7263 (cell)


View original content with multimedia:http://www.prnewswire.com/news-releases/nurses-nationwide-lend-a-helping-hand-at-bay-area-regional-in-the-aftermath-of-hurricane-harvey-300515985.html

SOURCE Bay Area Regional Medical Center

TSO3 Provides an Update on Recent Activities

QUEBEC CITY and MYRTLE BEACH, SC, Sept. 7, 2017 /PRNewswire/ - TSO3 Inc. (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, today announced that a major hospital in Canada has initiated terminal sterilization of duodenoscopes with the Company's STERIZONE® VP4 Sterilizer.  Additionally, the Company has successfully completed both a Quality System compliance inspection by US regulators and four weeks of comprehensive sales and marketing training with personnel from its exclusive distribution partner, the Getinge Group. 

The Company announced that the second largest hospital in Canada has completed the installation of multiple STERIZONE® VP4 Sterilizers and is now using these sterilizers to terminally process duodenoscopes used on patients undergoing endoscopic retrograde cholangio-pancreatography (ERCP) procedures. The Company's STERIZONE® VP4 Sterilizer is the only validated system cleared for the terminal sterilization of duodenoscopes (US claim pending clearance) as well as other complex multi-channeled flexible endoscopes such as colonoscopes and gastroscopes.

Terminal sterilization of duodenoscopes represents an entirely new level of patient protection as compared to the less robust disinfecting systems in use today. Disinfecting processes are under increasing public and regulatory scrutiny given a number of documented cases of duodenoscope-related patient-to-patient transfer of antibiotic resistant micro-organisms, some of which have led to patient deaths.

"For the first time in history, an industry leading medical facility is terminally sterilizing duodenoscopes using a validated process, a major advancement in healthcare and patient safety, and they are using TSO3 technology," stated R.M. (Ric) Rumble, TSO3's President and CEO.  "Terminal sterilization is now an option for healthcare facilities who are concerned about scope-related patient-to-patient transfer of contaminants.  Ineffective endoscope reprocessing is a pressing global healthcare issue and we believe sterilization is a major part of the solution.  TSO3 is now working with additional leading healthcare facilities in Canada, in the United States and in Europe on STERIZONE® VP4 Sterilizer installations for the specific purpose of terminally sterilizing duodenoscopes and other endoscopes."

TSO3 also announced the successful completion of a routine Quality System compliance inspection by US regulators.  The Company passed the inspection without any reportable findings – which is considerable given the rapid expansion of the Company.  The Company has and continues to follow a continuous improvement based regulatory compliance program which was commended by the regulators. 

Lastly, the Company announced the completion of a comprehensive four week training program for customer facing representatives from its exclusive distributor, the Getinge Group.  This training was conducted by in-house staff and satisfied medical facility end users.  It covered selling and marketing material, technical information, clinical input, and customer Q&A preparation. 

About the STERIZONE® VP4 Sterilizer

The STERIZONE® VP4 Sterilizer is a low-temperature sterilization system that utilizes the dual-sterilants of vaporized hydrogen peroxide (H2O2) and ozone (O3) to achieve terminal sterilization of heat and moisture sensitive medical devices. Its single pre-programmed cycle can sterilize a large number and wide range of compatible devices, creating a cost-effective sterilization process with error free cycle selection. The device's unique Dynamic Sterilant Delivery System™ automatically adjusts the quantity of injected sterilant based on the load composition, weight and temperature. This capability removes the guesswork and potential for human error, as there is no need to sort instruments and choose the appropriate cycles as with other machines.

The STERIZONE® VP4 Sterilizer is the only terminal sterilization method that is FDA cleared to sterilize multi-channeled flexible endoscopes (with a maximum of four channels) of up to 3.5 meters in length, such as video colonoscopes and gastroscopes - an industry first for any medical device sterilization process.

The STERIZONE® VP4 Sterilizer is also the only cleared low temperature sterilizer that can process a mixed load consisting of general instruments, single channel flexible endoscopes, and single or double channel rigid endoscopes in the same cycle with load weights of up to 75 lb.  The ability to run mixed loads significantly reduces labor costs by minimizing the amount of instrument sorting required, while maximizing the device turns (more productivity from increased throughput capacity).  More information about the STERIZONE® VP4 Sterilizer is available through TSO3's website, under the Products section at http://www.tso3.com/en/products/sterizone-vp4/.

About TSO3

Founded in 1998, TSO3's activities encompass the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. TSO3 also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.

For more information about TSO3, visit the Company's website at www.tso3.com.

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of TSO3's regulatory filings, revenue, business or operations) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, the ability of the Company to obtain the required regulatory clearances to market its products, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.  Although TSO3 believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. The complete versions of the cautionary note regarding forward-looking statements as well as a description of the relevant assumptions and risk factors likely to affect TSO3's actual or projected results are included in the Management's Discussion and Analysis for the year ended December 31, 2016, which is available on the Company's website. The forward-looking statements contained in this press release are made as of the date hereof and TSO3 does not assume any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise unless expressly required by applicable securities laws.



West Cancer Center and the University of Tennessee Health Science Center Welcome D. Neil Hayes, MD, MPH, to Lead The Cancer Research Initiative

Dr. Hayes to serve as Scientific Director, Medical Oncologist and the Van Vleet Endowed Professor

MEMPHIS, Tenn., Sept. 7, 2017 /PRNewswire-USNewswire/ -- West Cancer Center and the University of Tennessee Health Science Center (UTHSC), in partnership with St Jude Children's Research Hospital are proud and excited to announce the appointment of D. Neil Hayes, MD, MPH, as the Scientific Director of the UT-West Institute for Cancer Research, and the Van Vleet Endowed Professor in Medical Oncology in the Department of Medicine (Division of Hematology-Oncology) with secondary appointments in the Department of Genetics, Genomics, and Informatics (GGI) and the Department of Preventive Medicine in the College of Medicine (COM) of the University of Tennessee Health Science Center (UTHSC). Through these leadership roles and appointments, Dr. Hayes will direct and drive funding to lead scientific initiatives for discovery in translational research for the advancement of novel cancer treatment and therapies.

Dr. Hayes will assume direction of a $25 million dollar fund raised through the combined efforts of The West Cancer Center, University of Tennessee Health Science Center and Methodist Le Bonheur Health Care. He will utilize this fund to recruit additional scientists to the UT / West Institute for Cancer Research in service of a unique program of precision cancer medicine. West Cancer Center's ultimate goal is to become an NCI designated cancer center, which is anticipated to take seven to ten years with an additional investment of $100 million.  "Dr. Hayes will lead the scientific research and discovery portion of this journey, specifically launching a program to recruit scientists focused on genomic research for the development of more personalized cancer care," replied Dr. Lee Schwartzberg, the Executive Director of the West Cancer Center.

The recruitment of Dr. Hayes was a collaboration between healthcare leaders within the partnership and St Jude Children's Research Hospital.  "Our goal was to attract Neil because of his strong background in cancer genomics and his goal of moving genomic paradigms to clinical decision making. This molecular focus that involves bringing the result to the patient is the forefront of precision/personalized medicine in cancer and other areas. He will be the focus of this approach on the UTHSC campus and at West Cancer Center," stated Dr. David Stern, Robert Kaplan Executive Dean for the College of Medicine at UTHSC.  

Dr. Hayes most recently served as co-leader of the University of North Carolina (UNC) Lineberger Clinical Research Program, Professor in the Division of Hematology/Oncology and the Department of Otolaryngology/Head and Neck Cancer Surgery, and director of Clinical Bioinformatics at UNC. During his tenure at UNC Lineberger – a National Cancer Institute (NCI) Designated Comprehensive Cancer Center – Dr. Hayes successfully garnered over $40 million dollars in cancer research grants and funding, while simultaneously developing one of the most productive clinical trial programs for head and neck cancer in the nation. More broadly, Dr. Hayes currently is in his 10th year as a leader in efforts surrounding the Cancer Genome Atlas (TCGA), the pivotal genomic sequencing project of the decade. His most notable accomplishments in this area include co-leading the sequencing of RNA for most of the project, and a senior role in more than 20 manuscripts reported in Cell, Nature, and the New England Journal.  Dr. Hayes lists over 120 peer-reviewed manuscripts in the last decade in the field of cancer research and is most proud of his trainee record including more than 30 students and post-doctoral fellows. While at UNC Lineberger Clinical Research Program, Dr. Hayes began work in molecular profiling in lung and head and neck cancer that shows a wide range of potential clinical utility, including the ability to predict clinical outcomes for which there are currently no existing clinical diagnostic tests

Dr. Hayes will share his expertise with the next generation of cancer providers and scientists at UTHSC, where he will have a primary appointment as a professor in the Department of Internal Medicine, Division of Hematology/Oncology, and secondary appointments as a professor in the Department of Genetics, Genomics, and Informatics, and the Department of Preventive Medicine.  In terms of his collaboration with St. Jude, Dr. Hayes experience with gene expression and RNA analysis brings a unique skill set to the classification of tumors of any etiology.  We look forward to collaborations that leverage both his specific expertise as well as his broad experience in genomics and team science. Board certified in medical oncology, hematology and internal medicine, Dr. Hayes earned his medical degree from the top-rated University of North Carolina in Chapel Hill, NC. He completed his residency at Boston University School of Medicine and a clinical fellowship at Tufts England Medical Center, continuing his education with a postdoctoral fellowship at the NCI Designated Dana Farber Cancer Institute in Boston, Massachusetts. Dr. Hayes also holds a Master's of Public Health from Harvard School of Public Health and a Master's of Science from Tufts New England School of Medicine.

As he looks forward, however, Dr. Hayes stated his hopes to continue his work and pursue further cancer research initiatives at the UT/West Institute of Cancer Research with a hunger for revolutionary discovery. "While I stand proudly behind a record of success in my years at UNC, my enthusiasm for the future dwarfs the accomplishments to date."  

About the University of Tennessee/ West Institute for Cancer Research
The University of Tennessee/ West Institute for Cancer Research is a not-for-profit public charity dedicated to raising funds for adult cancer research. Located in Memphis, TN, the UT/West Institute for Cancer Research solicits grants (from government agencies, foundations and individuals) to be utilized to broaden cutting-edge research programs, develop novel cancer treatments and therapeutics, and strengthen patient-focused care in all sectors of the community. Funds donated to the UT/West Institute are designated for research in five major areas of emphasis: Translational Drug Discovery and Development, Cancer Immunotherapy, Women's Cancers, Community Outcomes and WINGS Supportive Care. The generous philanthropy of our donors and benefactors provides the necessary funding for West Cancer Center researchers to create and produce the most effective therapies for cancer patients, with the collective goal of defeating cancer in its entirety.

About West Cancer Center
West Cancer Center delivers the best comprehensive cancer treatment in the Mid-South, delivering a complete continuum of care to over 30,000 individuals annually. A true leader in cancer research, West Cancer Center has a long standing commitment to providing patients access to clinical trials which includes Phase I through Phase III studies. Building on the 35 year legacy of West Clinic, West Cancer Center continues to provide comprehensive, compassionate care to the Mid-South area. This commitment is strengthened through a robust partnership with Methodist Healthcare and the University of Tennessee Health Science Center.

For more information, please visit: www.westcancercenter.org.

About University of Tennessee Health Science Center 
As Tennessee's only public, statewide, academic health system, the mission of the University of Tennessee Health Science Center (UTHSC) is to bring the benefits of the health sciences to the achievement and maintenance of human health, with a focus on the citizens of Tennessee and the region, by pursuing an integrated program of education, research, clinical care, and public service. Offering a broad range of postgraduate and selected baccalaureate training opportunities, the main UTHSC campus is located in Memphis and includes six colleges: Dentistry, Graduate Health Sciences, Health Professions, Medicine, Nursing and Pharmacy. UTHSC also educates and trains cohorts of medicine, pharmacy and/or health professions students -- in addition to medical residents and fellows -- at its major sites in Knoxville, Chattanooga and Nashville. Founded in 1911, during its more than 100 years, UT Health Science Center has educated and trained more than 57,000 health care professionals in academic settings and health care facilities across the state. For more information, visit www.uthsc.edu. Follow us on Facebook: facebook.com/uthsc, on Twitter: twitter.com/uthsc and on Instagram: instagram.com/uthsc. 

West Cancer Center
Caitlin McCaskill
901.683.0055 ext. 61174


View original content:http://www.prnewswire.com/news-releases/west-cancer-center-and-the-university-of-tennessee-health-science-center-welcome-d-neil-hayes-md-mph-to-lead-the-cancer-research-initiative-300515964.html

SOURCE West Cancer Center

Bionik Laboratories Corp. Appoints Dr. Eric Dusseux as Chief Executive Officer

TORONTO and BOSTON, Sept. 7, 2017 /PRNewswire/ -- Bionik Laboratories Corp. (OTCQB: BNKL) ("Bionik" or the "Company"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced that the Board of Directors has appointed Dr. Eric Dusseux, a director of the Company since July 2017, as Chief Executive Officer, effective September 1, 2017.  Dr. Dusseux is a proven executive who has spent the past 15 years focused on helping companies in the healthcare sector develop and execute strategic growth and commercialization plans. Peter Bloch will continue to serve Bionik in the capacity as Chairman of the Board of Directors of the Company and will consult with the Company during the management transition.

"We are delighted that Eric has chosen to accept the role of Chief Executive Officer at Bionik," said Mr. Bloch.  "His proven entrepreneurial ability to drive commercialization and growth strategy in domestic and international markets, and his experience in building and leading strategic alliances will be significant assets for Bionik.  Eric's appointment coincides with our efforts to expand our global sales and marketing efforts and develop strategic distribution agreements and partnerships targeting hospital and mass markets."

Commenting on his appointment, Dr. Dusseux said, "I am excited to be joining the management team of Bionik at a very important time for the Company.  We believe that the approach that the Company has taken to focus on evidence-based medicine results ahead of sales and marketing efforts both provides validation for our products and differentiates us from other companies in our field.  I look forward to broadening our innovative clinical product platform and helping to bring our products under development from the hospital to the home as we pursue mass market opportunities."

About Eric Dusseux

Prior to joining Bionik, Dr. Dusseux was President of Europe and a director for Auregen BioTherapeutics SA, a 3D bioprinting tissue engineering biotechnology company headquartered in Switzerland, that he formed while at Bemido SA, a family office, with the support of Gurnet Point Capital and Waypoint.

From 2012 through 2016, Dr. Dusseux served as an Executive Committee Member in the Corporate Strategy Department of Sanofi Pasteur, the vaccine division of Sanofi.  Among other responsibilities, Dr. Dusseux, Vice-President Corporate Strategy, was responsible for business intelligence, strategic and business planning, and corporate development.

Before joining Sanofi Pasteur, Dr. Dusseux served as Vice-President, MAGE-A3 Medicines Development Leader, within the Immunotherapeutics Business Unit at GSK Biologicals, a division of GlaxoSmithKline, in charge of therapeutic vaccines against cancer.

Dr. Dusseux also gained significant experience providing strategic advice for numerous pharmaceutical, medical device, payer and biotechnology clients, while working for the Boston Consulting Group from 2002 to 2007.

Dr. Dusseux is a Medical Doctor, specializing in Public Health. Dr. Dusseux also holds a Master of Science in Physical Chemistry and is a graduate of the French Business School H.E.C. in Paris (MBA, Isa).

About Bionik Laboratories

Bionik Laboratories (OTCQB:BNKL) is a robotics company focused on providing rehabilitation and mobility solutions to individuals with neurological and mobility challenges from hospital to home. The Company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility-impaired patients, including three products on the market and four products in varying stages of development.

For more information, please visit www.bioniklabs.com and connect with us on TwitterLinkedIn, and Facebook. If you're a shareholder and wish to receive email alerts for Company news, please sign up here.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons and other robotic rehabilitation products, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the market and projected market for our existing and planned products and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions, and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.


View original content:http://www.prnewswire.com/news-releases/bionik-laboratories-corp-appoints-dr-eric-dusseux-as-chief-executive-officer-300514336.html

SOURCE Bionik Laboratories Corp.

Medifast, Inc. Announces Quarterly Dividend

OWINGS MILLS, Md., Sept. 7, 2017 /PRNewswire/ -- Medifast, Inc. (NYSE: MED), a leading provider of clinically studied healthy living products and programs, announced today that its Board of Directors has declared a $0.32 cash dividend to its stockholders. The quarterly cash dividend of $0.32 per share is payable on November 9, 2017 to stockholders of record as of the close of business on September 22, 2017.

The Company expects to maintain a program of paying dividends on a quarterly basis.  However, the declaration of dividends in the future is subject to the discretion of the Medifast Board of Directors, who will evaluate the Company's dividend program from time to time based on factors that it deems relevant.

About Medifast®:
Medifast (NYSE: MED) is a leading provider of clinically studied healthy living products and programs. It partners with OPTAVIA Coaches™ to help its clients achieve Optimal Health™ and Wellbeing through a comprehensive approach to Lifelong Transformation, One Healthy Habit at a Time™, with personal support and scientifically proven plans and Fuelings. Medifast was founded in 1980 in Owings Mills, Maryland and is the brand recommended by more than 20,000 Doctors since 1980. The company was named to the Forbes 100 Most Trustworthy Companies in America List in 2017 and 2016. For more information, visit www.MedifastNow.com.


Forward Looking Statements
This release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995.  These "forward-looking" statements generally can be identified by use of phrases or terminology such as "intend" or other similar words or the negative of such terminology. Similarly, descriptions of Medifast's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Medifast believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, Medifast's inability to attract and retain independent OPTAVIA Coaches and Members, stability in the pricing of print, TV and Direct Mail marketing initiatives affecting the cost to acquire customers, increases in competition, litigation, regulatory changes, and its planned growth into new domestic and international markets and new channels of distribution. Although Medifast believes that the expectations, statements, and assumptions reflected in these forward- looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest. Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

View original content with multimedia:http://www.prnewswire.com/news-releases/medifast-inc-announces-quarterly-dividend-300515959.html

SOURCE Medifast, Inc.

New Data Demonstrate Aimovig(TM) (erenumab) Reduced Monthly Migraine Days In Patients Who Failed Previous Preventive Therapies

Aimovig Reduced Monthly Migraine Days for Patients With Chronic Migraine and Prior Treatment Failure, a Population With Significant Unmet NeedResults From New Dedicated Cardiovascular Study Support Overall Safety Profile Observed in Aimovig Clinical Study ProgramAimovig is the Only Investigational Biologic Product Specifically Designed to Prevent Migraine by Blocking the CGRP Receptor, Which is Associated With Migraine Activation

THOUSAND OAKS, Calif., Sept. 7, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data in patients with high unmet need, providing further evidence of the efficacy of Aimovig™* (erenumab) for migraine prevention. Aimovig is the first and only investigational biologic product specifically designed to prevent migraine by blocking the calcitonin gene-related peptide (CGRP) receptor, which is associated in migraine activation. The data include a pre-planned sub-analysis from the pivotal Phase 2 chronic migraine study, demonstrating that Aimovig reduced the number of monthly migraine days (MMDs) in patients who have failed previous preventive therapies. Additionally, results from a dedicated study in patients with stable angina adds further support to the safety profile of Aimovig. These results will be presented at the 18th Congress of the International Headache Society in Vancouver, Canada.

"Data from our robust clinical development program continue to show that Aimovig has demonstrated efficacy in a broad range of patients, including hard-to-treat chronic migraine sufferers who have previously tried and failed other preventive therapies," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "Separately, new results from a treadmill safety study showed no adverse cardiovascular effect compared to placebo in patients with coronary artery disease and stable angina, which complements our extensive safety database and ongoing long-term extension studies of Aimovig for migraine prevention."

Studies have shown that up to 80 percent of people with migraine discontinue preventive treatment within one year. In a pre-specified sub-analysis from the Phase 2 study, Aimovig showed benefits for people with chronic migraine who have previously tried and failed preventive treatments. At the end of the 12-week study, patients who had failed two or more prior preventive treatments experienced a reduction of 7.0 days and 5.4 days in the Aimovig 140 mg and 70 mg, respectively, compared to placebo reduction of 2.7 days (p<0.001). Furthermore, in the Aimovig treated arms, the odds of cutting migraine days in at least half was three-to-four fold higher than in the placebo arm (140 mg: 41.3 percent, 70 mg: 35.6 percent, placebo: 14.2 percent (p<0.001 for both doses versus placebo). 

The safety profile of Aimovig was similar to placebo across both treatment arms in the Phase 2 study. No adverse event was reported in greater than five percent of patients treated with Aimovig; the most common adverse events were injection site pain, upper respiratory tract infection and nausea.

Aimovig was tested in a group of patients with stable angina due to coronary artery disease. A treadmill "stress test" is often used to gauge how well a patient's heart can handle exercise. The study met it primary endpoint of noninferiority, showing no difference in exercise time among participants receiving Aimovig or placebo. The treatment difference in mean change from baseline in exercise time was –11.0 seconds (90 percent confidence interval –44.9, 22.9). In addition, no significant differences were seen between the two groups in time to onset of angina or time to onset of electrocardiogram change consistent with onset of myocardial ischemia. Adverse events were reported in 27 percent of patients receiving Aimovig and in 32 percent of patients receiving placebo. The most frequent treatment-emergent adverse events (reported in >2 percent of patients) were headache (4.5 percent) and viral upper respiratory infection (4.5 percent) in the Aimovig group, and were hypotension (4.5 percent), influenza (4.5 percent) and viral infection (4.5 percent) in the placebo group.

"While the community has watched the next generation of migraine preventives with excitement, because CGRP has a vasodilatory effect, there have been questions about a potential impact on cardiovascular function especially in at-risk populations," said Amaal J. Starling, M.D., assistant professor of neurology at the Mayo Clinic in Scottsdale, Ariz., and a study co-author. "The results of this study provide some evidence that CGRP receptor inhibition did not aggravate myocardial ischemia in at-risk population of patients with stable angina compared to placebo and contribute to the growing body of evidence supporting the safety profile of Aimovig."

These results are consistent with the known safety profile of Aimovig, as seen across the broad clinical program involving more than 2,600 migraine patients.

Regulatory submissions for Aimovig have been filed in the United States (U.S.) and Europe. The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of May 17, 2018. If approved, Novartis and Amgen will co-commercialize Aimovig in the U.S. Amgen has exclusive commercialization rights to the drug in Japan and Novartis has exclusive rights to commercialize in rest of world.

About Aimovig™ (erenumab)

Aimovig is the only investigational biologic product specifically designed to prevent migraine by blocking the CGRP receptor, which is associated with migraine activation. Aimovig has been studied in several large global, randomized, double-blind, placebo-controlled studies to assess its safety and efficacy in migraine prevention. More than 2,600 patients have been exposed to Aimovig across the four placebo-controlled Phase 2 and Phase 3 clinical studies and their open-label extension.

About the Phase 2 Study

The 20120295 study is a global Phase 2, randomized, 12-week, double-blind, placebo-controlled study evaluating the safety and efficacy of Aimovig in chronic migraine prevention. In the study, 667 patients were randomized to receive once-monthly subcutaneous placebo or Aimovig (70 mg or 140 mg) in a 3:2:2 ratio, respectively. The primary endpoint was change in MMDs from baseline to the last four weeks of the 12-week treatment phase in patients with chronic migraine (the number of migraine days between weeks nine and 12). Secondary study endpoints included reduction of at least 50 percent from baseline in monthly migraine days, change from baseline in monthly acute migraine-specific medication days and change from baseline in cumulative monthly headache hours.

About the Treadmill Cardiovascular Safety Study

The 20140254 study is a double-blind, placebo-controlled cardiovascular safety study in patients with stable angina due to documented coronary artery disease. Patients were randomized 1:1 to a single intravenous infusion of Aimovig 140 mg or placebo stratified by baseline treadmill exercise test (TET) (<7 minutes or ≥7 minutes) defined as the average TET of two qualifying exercise tolerance tests (ETTs) performed during screening. Following study drug administration on Day 1, a post-administration ETT was conducted. The primary endpoint was the change from baseline in exercise duration as measured by TET with a non-inferiority margin of –90 seconds. Secondary efficacy endpoints included time to onset of ≥1 mm ST-segment depression and time to onset of exercise-induced angina during the ETT. Safety follow-up visits occurred every 2-4 weeks for 12 weeks. Adverse events were reported by 14 percent of Aimovig-treated patients and by 27 percent of placebo patients and were consistent with the known safety profile of erenumab.

About Migraine

People with frequent migraine may lose more than half their life to migraine days.1 Migraine robs individuals of time with their families, and impacts their daily activities at home and at work. Migraine patients endure debilitating pain, incapacitating physical impairment, and live in constant dread of the next attack – all of which is compounded by a widespread misperception of the disease.2 The World Health Organization ranks migraine as one of the most debilitating illnesses.2 For the approximately 10 million Americans whose migraine frequency or severity impacts daily activities, preventive medications may be an option.3 Approximately 3.5 million of these patients are currently on a preventive therapy, but up to 80 percent discontinue these within one year.3,4 Migraine is associated with personal and societal burdens of pain, disability, and financial cost, and it remains under-recognized and under-treated.

About Amgen and Novartis Neuroscience Collaboration

Since 2015, Amgen and Novartis have collaborated to jointly develop and commercialize pioneering treatments in the field of migraine and Alzheimer's disease (AD). This includes investigational Amgen drugs in the migraine field, including Aimovig (Biologics License Application accepted by the FDA in July 2017) and AMG 301 (currently in Phase 1 development). In April 2017, the collaboration was expanded to include co-commercialization of Aimovig in the U.S. For the migraine program, Amgen retains exclusive rights in Japan, and Novartis has exclusive rights in Europe, Canada and rest of world. The companies are also partnering in the development and commercialization of a beta-secretase 1 (BACE) inhibitor program in AD.

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Forward-Looking Statements

This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.

Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to acquire other companies or products and to integrate the operations of companies we have acquired may not be successful. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. We are increasingly dependent on information technology systems, infrastructure and data security. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock.

The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration, and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates.

*The trade name Aimovig™ is provisionally approved for use by the U.S. FDA.

CONTACT: Amgen, Thousand Oaks
Kristen Davis, 805-447-3008 (media)
Kristen Neese, 805-313-8267 (media)
Arvind Sood, 805-447-1060 (investors)

1 Lipton RB, et al. Migraine prevalence, disease burden, and the need for preventative therapy. Neurology. 2007; 68(5):343-9.
2 Headache disorders - Fact sheets. World Health Organization. http://www.who.int/mediacentre/factsheets/fs277/en/. Accessed March 3, 2017.
3 Marketscan data on file. March 31, 2017. Ref Type: Data File
4 Hepp Z et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015; 35(6):478-88.


View original content with multimedia:http://www.prnewswire.com/news-releases/new-data-demonstrate-aimovig-erenumab-reduced-monthly-migraine-days-in-patients-who-failed-previous-preventive-therapies-300515926.html